Literature DB >> 27890725

Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.

Srikrishnan Mallipeddi1, David R Janero1, Nikolai Zvonok1, Alexandros Makriyannis2.   

Abstract

The phenomenon of functional selectivity, whereby a ligand preferentially directs the information output of a G-protein coupled receptor (GPCR) along (a) particular effector pathway(s) and away from others, has redefined traditional GPCR signaling paradigms to provide a new approach to structure-based drug design. The two principal cannabinoid receptors (CBRs) 1 and 2 belong to the class-A GPCR subfamily and are considered tenable therapeutic targets for several indications. Yet conventional orthosteric ligands (agonists, antagonists/inverse agonists) for these receptors have had very limited clinical utility due to their propensity to incite on-target adverse events. Chemically distinct classes of cannabinergic ligands exhibit signaling bias at CBRs towards individual subsets of signal transduction pathways. In this review, we discuss the known signaling pathways regulated by CBRs and examine the current evidence for functional selectivity at CBRs in response to endogenous and exogenous cannabinergic ligands as biased agonists. We further discuss the receptor and ligand structural features allowing for selective activation of CBR-dependent functional responses. The design and development of biased ligands may offer a pathway to therapeutic success for novel CBR-targeted drugs. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biased agonism; Drug discovery; Effector pathways; GPCR

Mesh:

Substances:

Year:  2016        PMID: 27890725      PMCID: PMC5470118          DOI: 10.1016/j.bcp.2016.11.014

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  120 in total

1.  Coupling of the expressed cannabinoid CB1 and CB2 receptors to phospholipase C and G protein-coupled inwardly rectifying K+ channels.

Authors:  B Y Ho; Y Uezono; S Takada; I Takase; F Izumi
Journal:  Receptors Channels       Date:  1999

2.  Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy.

Authors:  Emma T van der Westhuizen; Billy Breton; Arthur Christopoulos; Michel Bouvier
Journal:  Mol Pharmacol       Date:  2013-12-23       Impact factor: 4.436

Review 3.  Cannabinoids and ceramide: two lipids acting hand-by-hand.

Authors:  Guillermo Velasco; Ismael Galve-Roperh; Cristina Sánchez; Cristina Blázquez; Amador Haro; Manuel Guzmán
Journal:  Life Sci       Date:  2005-08-19       Impact factor: 5.037

Review 4.  The role of endocannabinoids in the hypothalamic regulation of visceral function.

Authors:  T Wenger; G Moldrich
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2002 Feb-Mar       Impact factor: 4.006

5.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

6.  Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor.

Authors:  Georgina L Thompson; J Robert Lane; Thomas Coudrat; Patrick M Sexton; Arthur Christopoulos; Meritxell Canals
Journal:  Biochem Pharmacol       Date:  2016-06-07       Impact factor: 5.858

Review 7.  The role of protein dynamics in GPCR function: insights from the β2AR and rhodopsin.

Authors:  Aashish Manglik; Brian Kobilka
Journal:  Curr Opin Cell Biol       Date:  2014-02-17       Impact factor: 8.382

8.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

Review 9.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

Review 10.  Design of Next-Generation G Protein-Coupled Receptor Drugs: Linking Novel Pharmacology and In Vivo Animal Models.

Authors:  Sophie J Bradley; Andrew B Tobin
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

View more
  22 in total

1.  Deletion of Type-2 Cannabinoid Receptor Induces Alzheimer's Disease-Like Tau Pathology and Memory Impairment Through AMPK/GSK3β Pathway.

Authors:  Lin Wang; Bing-Jin Liu; Yun Cao; Wei-Qi Xu; Dong-Sheng Sun; Meng-Zhu Li; Fang-Xiao Shi; Man Li; Qing Tian; Jian-Zhi Wang; Xin-Wen Zhou
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

2.  Cannabichromene is a cannabinoid CB2 receptor agonist.

Authors:  Michael Udoh; Marina Santiago; Steven Devenish; Iain S McGregor; Mark Connor
Journal:  Br J Pharmacol       Date:  2019-11-21       Impact factor: 8.739

Review 3.  Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.

Authors:  Janos Paloczi; Zoltan V Varga; George Hasko; Pal Pacher
Journal:  Antioxid Redox Signal       Date:  2017-07-18       Impact factor: 8.401

4.  Computational insights into the subtype selectivity and "message-address-efficacy" mechanisms of opioid receptors through JDTic binding and unbinding.

Authors:  Jian-Xin Cheng; Tao Cheng; Wei-Hua Li; Gui-Xia Liu; Wei-Liang Zhu; Yun Tang
Journal:  Acta Pharmacol Sin       Date:  2017-10-19       Impact factor: 6.150

Review 5.  Biased signalling: from simple switches to allosteric microprocessors.

Authors:  Jeffrey S Smith; Robert J Lefkowitz; Sudarshan Rajagopal
Journal:  Nat Rev Drug Discov       Date:  2018-01-05       Impact factor: 84.694

6.  Pyrimidinyl Biphenylureas Act as Allosteric Modulators to Activate Cannabinoid Receptor 1 and Initiate β-Arrestin-Dependent Responses.

Authors:  Caitlin A D Jagla; Caitlin E Scott; Yaliang Tang; Changjiang Qiao; Gabriel E Mateo-Semidey; Guillermo A Yudowski; Dai Lu; Debra A Kendall
Journal:  Mol Pharmacol       Date:  2018-10-15       Impact factor: 4.436

7.  Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds.

Authors:  Elise Wouters; Jolien Walraed; Michael Joseph Robertson; Max Meyrath; Martyna Szpakowska; Andy Chevigné; Georgios Skiniotis; Christophe Stove
Journal:  ACS Pharmacol Transl Sci       Date:  2019-11-04

8.  THC Reduces Ki67-Immunoreactive Cells Derived from Human Primary Glioblastoma in a GPR55-Dependent Manner.

Authors:  Marc Richard Kolbe; Tim Hohmann; Urszula Hohmann; Chalid Ghadban; Ken Mackie; Christin Zöller; Julian Prell; Jörg Illert; Christian Strauss; Faramarz Dehghani
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.639

9.  Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.

Authors:  Marja D Sepers; Amy Smith-Dijak; Jeff LeDue; Karolina Kolodziejczyk; Ken Mackie; Lynn A Raymond
Journal:  J Neurosci       Date:  2017-11-30       Impact factor: 6.167

Review 10.  Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor.

Authors:  Dai Lu; Sri Sujana Immadi; Zhixing Wu; Debra A Kendall
Journal:  Acta Pharmacol Sin       Date:  2018-10-17       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.